Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin benefits patients with type 2 diabetes mellitus (T2DM) with prior MI, heart failure with reduced ejection fraction (HFrEF) or peripheral arterial disease (PAD), according to results of subanalyses of the DECLARE-TIMI 58 trial presented at the American College of Cardiology’s 68th Annual Scientific Session.
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
Among patients with a recent acute ischaemic stroke treated with thrombolytic therapy, intensive blood pressure (BP)-lowering conferred no additional benefit in functional recovery compared with guideline-recommended BP-lowering, despite a reduced risk of intracranial haemorrhage with intensive therapy, according to results of the ENCHANTED* trial.
Among patients with a history of stroke, an intensive blood pressure-lowering regimen did not reduce the risk of recurrent stroke compared with a standard blood pressure-lowering regimen, according to results of the RESPECT* trial presented at ISC 2019.